8-K
Current Report
CRISPR Therapeutics AG Filed Acc 0001193125-19-324924
Agreement ended · Executive or director change
- Item 1.02 Termination of a material definitive agreement
- Item 5.02 Departure or appointment of directors or officers
From the SEC's structured data for this filing
Loading d860203d8k.htm…